

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT
FINANCIAL RESULTS FOR THE THIRD QUARTER
ENDED 30 SEPTEMBER 2025 OF A LISTED ASSOCIATE
- LEGEND BIOTECH CORPORATION**

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”).

Legend Biotech Corporation (“**Legend**”), an associate of the Company, whose shares are listed by way of American Depository Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) on 12 November 2025 in relation to the financial results of Legend for the third quarter ended 30 September 2025 and the recent business highlights. For details, please refer to the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000180119825000031/0001801198-25-000031-index.html>.

Shareholders should note that the above financial results pertain only to Legend not to the Company itself.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 12 November 2025

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“**Mr. Robin Meng**”), Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Dr. Li Zhu and Ms. Ye Wang (“**Ms. Sally Wang**”); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“**Dr. Victor Shi**”).*